Comparing Two Budesonide Nasal Sprays
Author Information
Author(s): Algorta Jaime, Pena Maria Angeles, Francisco Silvia, Abajo Zurine, Sanz Emilio
Primary Institution: Clinical Trials Unit, Fundacion LEIA-Txagorritxu Hospital, Vitoria-Gasteiz, Spain
Hypothesis
The study aims to compare the systemic availability, pharmacodynamic effect, and safety of two intranasal budesonide formulations for the treatment of rhinitis.
Conclusion
The systemic availability of intranasal budesonide was comparable for both formulations in terms of most pharmacokinetic parameters, and side effects were similar.
Supporting Evidence
- Both formulations showed comparable pharmacokinetic parameters.
- No severe adverse events were reported during the study.
- The pharmacodynamic effects on cortisol levels were similar for both formulations.
Takeaway
This study tested two types of nasal sprays with the same medicine to see if they work the same way in the body, and they found that they do.
Methodology
Eighteen healthy volunteers participated in a randomised, controlled, crossover trial where they received two different formulations of budesonide on separate days.
Limitations
The study had a small sample size and was conducted only in healthy volunteers, which may not represent all patients with rhinitis.
Participant Demographics
18 healthy adult volunteers (10 male and 8 female; mean age 24 years, range 19–39 years), all Caucasian.
Statistical Information
Confidence Interval
0.75–1.33
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website